Share This Page
Suppliers and packagers for IVRA
✉ Email this page to a colleague
IVRA
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Apotex | IVRA | melphalan hydrochloride | SOLUTION;INTRAVENOUS | 217110 | NDA | Apotex Corp | 60505-6414-1 | 1 VIAL, MULTI-DOSE in 1 CARTON (60505-6414-1) / 3 mL in 1 VIAL, MULTI-DOSE | 2025-05-09 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: IVRA (Intravenous Regional Anesthesia)
Introduction
Intravenous Regional Anesthesia (IVRA), commonly known as Bier Block, is a regional anesthesia technique used to anesthetize limbs during surgical procedures. It involves the administration of local anesthetics into a venous system isolated with a tourniquet, providing effective analgesia with rapid onset and minimal systemic toxicity. As a specialized modality predominantly used in orthopedic and minor surgical procedures, the supply chain for IVRA drugs, primarily local anesthetics, is critical for healthcare providers seeking reliable, high-quality pharmaceuticals.
This comprehensive review explores the leading suppliers of IVRA agents, focusing on key pharmaceutical companies, their product offerings, global reach, regulatory approvals, and market dynamics influencing supply stability.
The Core Pharmaceutical Agents in IVRA
The primary agents used for IVRA include local anesthetics like:
- Lidocaine (Lignocaine)
- Prilocaine
- Mepivacaine
- Bupivacaine
Among these, lidocaine and prilocaine dominate due to their efficacy, safety profile, and widespread availability.
Major Suppliers of IVRA Drugs
1. Aspen Pharmacare
Overview: Aspen Pharmacare, based in South Africa, has become a prominent supplier of local anesthetics, including lidocaine and prilocaine. Their formulations are used globally, particularly in emerging markets.
Product Portfolio:
- Lidocaine Hydrochloride 1% and 2% solutions
- Prilocaine HCl 0.5% and 0.75%
Market Reach:
Aspen's distribution network spans over 150 countries, emphasizing affordability and accessibility—a crucial factor in developing regions. Their products are often preferred for their cost-effectiveness without compromising quality.
2. Hospira (part of Pfizer)
Overview:
Hospira, now a Pfizer subsidiary, is a leading provider of injectable pharmaceuticals, including local anesthetics used in IVRA.
Product Portfolio:
- Lidocaine HCl 1% and 2% solutions
- Bupivacaine HCl
Regulatory and Quality Assurance:
Hospira's manufacturing adheres to stringent FDA, European Medicines Agency (EMA), and other international standards, ensuring high-quality pharmaceuticals.
3. Hikma Pharmaceuticals
Overview:
Hikma is a global generics manufacturer based in Jordan with a significant presence in Europe, the Middle East, and Africa.
Product Portfolio:
- Lidocaine injections in various concentrations
- Prilocaine solutions
Supply Stability:
Hikma’s widespread manufacturing facilities ensure steady supply and competitive pricing, making them a major player in the IVRA market.
4. Fresenius Kabi
Overview:
Fresenius Kabi, based in Germany, specializes in infusion therapies and anesthetics.
Product Portfolio:
- Lidocaine HCl injections, often used in IVRA procedures
- Other local anesthetic agents
Global Presence:
Fresenius’s extensive global manufacturing footprint supports reliable supply to both developed and developing markets.
5. Boehringer Ingelheim
Overview:
A historic pharmaceutical company based in Germany, Boehringer Ingelheim offers local anesthetics including lidocaine and prilocaine for regional anesthesia.
Product Portfolio:
- Lidocaine injections
- Prilocaine formulations
Quality Credentials:
Their longstanding reputation emphasizes advanced research, high-quality standards, and regulatory compliance.
Emerging and Regional Suppliers
While multinational corporations dominate the supply landscape, regional producers also supply IVRA agents, especially in emerging markets.
6. TEVA Pharmaceuticals
Overview:
Based in Israel, TEVA offers cost-effective local anesthetics with robust manufacturing capabilities.
Role in IVRA Supply:
TEVA’s lidocaine and prilocaine solutions are utilized in hospitals globally, especially where affordability is prioritized.
7. Shenghai Pharmaceutical
Overview:
A leading Chinese manufacturer of injectable pharmaceuticals.
Relevance:
Their local anesthetic products meet regulatory standards and are increasingly prevalent in Asian markets.
Market Dynamics and Supply Chain Considerations
The IVRA drug market primarily operates in a highly regulated environment, with manufacturers adhering to Good Manufacturing Practices (GMP). Supply chain stability depends on factors such as:
- Regulatory approvals and compliance: Variability in approvals across jurisdictions can impact availability.
- Manufacturing capacity: Global manufacturers with multiple production sites tend to have more resilient supply chains.
- Pricing pressures: The demand for cost-effective solutions, especially in emerging markets, affects supplier competition.
- Innovation and formulation improvements: Companies investing in novel formulations and delivery mechanisms influence the competitive landscape.
Regulatory and Quality Assurance
Suppliers must achieve approvals from agencies such as the FDA, EMA, or equivalent local authorities. These certifications confirm the safety, efficacy, and quality of IVRA agents.
- FDA: Ensures compliance with U.S. standards for injectable drugs.
- EMA: Regulates European pharmaceutical products.
- National authorities: Such as the South African Health Products Regulatory Authority (SAHPRA), or China's CFDA.
High-quality suppliers also engage in continuous quality monitoring, stability testing, and batch validation.
Supply Chain Challenges and Opportunities
The supply of IVRA drugs faces challenges including:
- Global supply chain disruptions, exemplified by pandemics impacting manufacturing and distribution.
- Regulatory delays in approval for biosimilars or new formulations.
- Price fluctuations driven by raw material costs.
Opportunities for stakeholders involve:
- Investing in regional manufacturing hubs to ensure local supply.
- Developing fixed-dose formulations for enhanced stability and ease of use.
- Expanding distribution networks to underserved regions.
Conclusion
The global IVRA drug supply ecosystem is characterized by a handful of major suppliers, predominantly multinational pharmaceutical giants such as Aspen Pharmacare, Pfizer (Hospira), Hikma Pharmaceuticals, Fresenius Kabi, and Boehringer Ingelheim. These companies’ high standards of quality, regulatory compliance, and extensive distribution networks underpin the reliability of IVRA agents worldwide.
Regional manufacturers like TEVA and Shenghai Pharmaceuticals supplement these supplies, especially in emerging markets, offering cost-effective options while meeting international standards. The evolving landscape demands continuous attention to manufacturing capacity, regulatory environments, and supply chain resilience to ensure uninterrupted access to quality IVRA medications.
Key Takeaways
- Major global suppliers of IVRA drugs include Aspen Pharmacare, Hospira (Pfizer), Hikma, Fresenius Kabi, and Boehringer Ingelheim.
- Ensuring regulatory compliance and high manufacturing standards is critical in supplier selection.
- Regional suppliers bolster supply chains in emerging markets, influencing pricing and availability.
- Supply disruptions, regulatory delays, and raw material costs are ongoing challenges.
- Investing in regional manufacturing, formulation innovation, and diversified supply networks enhances supply resilience.
FAQs
1. How do I verify the authenticity of IVRA drugs from suppliers?
Always verify supplier approvals through regulatory agencies such as the FDA or EMA. Purchasing from WHO-prequalified suppliers or those with recognized Good Manufacturing Practice (GMP) certification ensures authenticity.
2. Are there differences in efficacy among IVRA agents from various suppliers?
The active pharmaceutical ingredients (APIs) are standardized, so efficacy largely depends on formulation quality, concentration, and proper administration. Reputable suppliers adhere to strict standards ensuring consistent efficacy.
3. What should a hospital consider when selecting a supplier for IVRA drugs?
Factors include regulatory approvals, product quality certifications, supply stability, cost-effectiveness, and after-sales support.
4. Is there an increasing trend toward biosimilars or alternative formulations for IVRA?
While biosimilars are more prevalent in biologic therapies, the focus for local anesthetics remains on improved formulations, such as sustained-release versions, to enhance efficacy and safety.
5. How do geopolitical factors influence the IVRA drug supply chain?
Trade policies, tariffs, and political stability can affect manufacturing operations and distribution channels, impacting supply availability and pricing. Diversification of suppliers mitigates these risks.
Sources:
[1] Aspen Pharmacare. Company Website.
[2] Pfizer. Hospira Product Portfolio.
[3] Hikma Pharmaceuticals. Product Catalog.
[4] Fresenius Kabi. Annual Report.
[5] Boehringer Ingelheim. Corporate Overview.
More… ↓
